Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908773 · ClinicalTrials.gov registry record · Early Phase 1
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
A Early Phase 1 study, sponsored by TransCode Therapeutics.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05908773: Completed Early Phase 1 study, sponsored by TransCode Therapeutics.
NCT05908773 is a Early Phase 1 study that has completed, run by TransCode Therapeutics. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05908773, a Early Phase 1 study, has completed, sponsored by TransCode Therapeutics.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists of 3 parts: a screening period, dosing period, and follow-up period. The estimated total duration of the study is approximately 46 days. Approximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single site.
Primary Outcome
Measure the percent injected dose per cubic centimeter (%ID/cc) tissue of TTX-MC138-NODAGA-Cu64 in radiographically confirmed metastatic lesions in subjects with advanced solid tumors using PET-MRI.
Interventions
- DRUG TTX-MC138-NODAGA-Cu64
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2023-09-18 |
| Phase | Early Phase 1 |
What the finished NCT05908773 record still lists
NCT05908773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which TTX-MC138-NODAGA-Cu64 is the first listed.
NCT05908773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05908773 about?
NCT05908773 is a clinical study titled "A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors". This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases. The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 a...
What is the current status of trial NCT05908773?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-04-04. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT05908773?
The interventions under investigation include: TTX-MC138-NODAGA-Cu64 (DRUG).
Who is sponsoring clinical trial NCT05908773?
This trial is sponsored by TransCode Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05908773's enrollment target sits among peer trials
1 1986th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI